Several studies have shown that active demyelinating plaques, as well as serum and CSF of MS patients, express higher levels of CXCR3 and CCR5, while CCR4 expression, associated with T helper 2 (Th2) cells, is significantly reduced. The gene discussed is CCR5; the disease is myeloid sarcoma.